 William Robinson
Concepts (851)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 94 | 2026 | 757 | 6.960 |
Why?
| | Skin Neoplasms | 49 | 2025 | 850 | 3.830 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 72 | 1.610 |
Why?
| | Mastocytosis | 3 | 2021 | 14 | 1.380 |
Why?
| | Antineoplastic Agents | 19 | 2024 | 2201 | 1.070 |
Why?
| | Spinal Fusion | 4 | 2022 | 258 | 0.880 |
Why?
| | Melanocytes | 7 | 2024 | 65 | 0.840 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2025 | 211 | 0.770 |
Why?
| | Mutation | 17 | 2022 | 4081 | 0.750 |
Why?
| | Vitiligo | 5 | 2024 | 42 | 0.720 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 61 | 0.710 |
Why?
| | Thoracic Vertebrae | 2 | 2020 | 79 | 0.710 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1505 | 0.710 |
Why?
| | Proto-Oncogene Proteins B-raf | 7 | 2025 | 224 | 0.680 |
Why?
| | Mucous Membrane | 2 | 2024 | 128 | 0.680 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.660 |
Why?
| | Piperazines | 7 | 2018 | 378 | 0.640 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 40 | 0.620 |
Why?
| | Spinal Fractures | 1 | 2020 | 75 | 0.590 |
Why?
| | Middle Aged | 94 | 2024 | 35971 | 0.580 |
Why?
| | Exome | 2 | 2017 | 227 | 0.580 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 176 | 0.580 |
Why?
| | Humans | 211 | 2026 | 144667 | 0.570 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 29 | 0.570 |
Why?
| | Intervertebral Disc Displacement | 1 | 2019 | 41 | 0.560 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.550 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 26 | 0.540 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 72 | 0.540 |
Why?
| | Osteoporosis | 2 | 2020 | 236 | 0.540 |
Why?
| | Humeral Head | 1 | 2017 | 20 | 0.530 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 16 | 0.520 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 41 | 0.520 |
Why?
| | Orthopedics | 1 | 2020 | 168 | 0.520 |
Why?
| | Skin Pigmentation | 4 | 2024 | 48 | 0.510 |
Why?
| | Genetic Predisposition to Disease | 5 | 2019 | 2350 | 0.500 |
Why?
| | Intention | 1 | 2019 | 187 | 0.500 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2024 | 70 | 0.500 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 66 | 0.500 |
Why?
| | Granulocytes | 26 | 1988 | 81 | 0.490 |
Why?
| | Female | 120 | 2026 | 78304 | 0.490 |
Why?
| | Hematopoiesis | 24 | 1988 | 193 | 0.480 |
Why?
| | Databases, Factual | 4 | 2020 | 1494 | 0.480 |
Why?
| | MicroRNAs | 4 | 2023 | 689 | 0.480 |
Why?
| | Forecasting | 2 | 2017 | 391 | 0.470 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 17 | 0.460 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 117 | 0.450 |
Why?
| | Shoulder Joint | 1 | 2017 | 199 | 0.450 |
Why?
| | Osteoarthritis | 1 | 2017 | 196 | 0.440 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 101 | 0.440 |
Why?
| | Adult | 95 | 2025 | 40489 | 0.440 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1319 | 0.440 |
Why?
| | Phosphoproteins | 1 | 2017 | 339 | 0.430 |
Why?
| | Pyrimidines | 4 | 2008 | 519 | 0.420 |
Why?
| | Male | 101 | 2025 | 72431 | 0.420 |
Why?
| | Lysophospholipids | 2 | 2026 | 78 | 0.420 |
Why?
| | Aged | 63 | 2024 | 25955 | 0.410 |
Why?
| | Colony-Stimulating Factors | 20 | 1988 | 37 | 0.400 |
Why?
| | Aged, 80 and over | 21 | 2021 | 8284 | 0.400 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.390 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 3523 | 0.390 |
Why?
| | Nevus | 3 | 2010 | 26 | 0.390 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 407 | 0.370 |
Why?
| | Milk, Human | 1 | 2014 | 172 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 41 | 0.350 |
Why?
| | Pyrroles | 3 | 2021 | 213 | 0.340 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 39 | 0.340 |
Why?
| | Triazines | 2 | 2021 | 49 | 0.330 |
Why?
| | Military Personnel | 1 | 2019 | 733 | 0.330 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1437 | 0.330 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 70 | 0.320 |
Why?
| | Breast Neoplasms | 8 | 2017 | 2365 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1961 | 0.320 |
Why?
| | Lymph Node Excision | 5 | 2021 | 173 | 0.320 |
Why?
| | Sulfonamides | 4 | 2020 | 579 | 0.320 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 49 | 0.310 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 334 | 0.310 |
Why?
| | Genes, p16 | 3 | 2007 | 13 | 0.310 |
Why?
| | Adenocarcinoma | 5 | 2016 | 923 | 0.300 |
Why?
| | Lumbar Vertebrae | 3 | 2022 | 252 | 0.300 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 552 | 0.290 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1705 | 0.290 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 83 | 0.290 |
Why?
| | Uveal Neoplasms | 2 | 2026 | 16 | 0.290 |
Why?
| | Leukocytes | 14 | 1986 | 294 | 0.280 |
Why?
| | Lumbosacral Region | 2 | 2019 | 59 | 0.280 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 9 | 0.280 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 201 | 0.270 |
Why?
| | Tumor Suppressor Proteins | 4 | 2024 | 319 | 0.270 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 33 | 0.270 |
Why?
| | Treatment Outcome | 15 | 2022 | 11735 | 0.270 |
Why?
| | Cyclins | 1 | 2008 | 79 | 0.270 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 619 | 0.270 |
Why?
| | Nitrophenols | 3 | 2017 | 30 | 0.270 |
Why?
| | Quality Improvement | 2 | 2018 | 1287 | 0.260 |
Why?
| | Tretinoin | 4 | 2023 | 124 | 0.260 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 53 | 0.260 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 66 | 0.260 |
Why?
| | Pyrazoles | 2 | 2021 | 512 | 0.250 |
Why?
| | Tamoxifen | 3 | 2016 | 191 | 0.250 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 337 | 0.250 |
Why?
| | Prognosis | 14 | 2024 | 4312 | 0.250 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 47 | 0.240 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 93 | 0.240 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2026 | 53 | 0.240 |
Why?
| | Interferon-alpha | 6 | 2006 | 194 | 0.230 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2022 | 372 | 0.230 |
Why?
| | Hair Color | 2 | 2024 | 14 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 238 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2025 | 35 | 0.220 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 158 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 925 | 0.220 |
Why?
| | Epidermis | 2 | 2024 | 157 | 0.220 |
Why?
| | Liposarcoma | 1 | 2005 | 31 | 0.220 |
Why?
| | Mice | 29 | 2026 | 18261 | 0.220 |
Why?
| | Follow-Up Studies | 12 | 2020 | 5414 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 394 | 0.210 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 30 | 0.210 |
Why?
| | Intestine, Small | 2 | 2024 | 167 | 0.210 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1047 | 0.210 |
Why?
| | Ultraviolet Rays | 4 | 2024 | 384 | 0.210 |
Why?
| | Dasatinib | 1 | 2024 | 57 | 0.210 |
Why?
| | Hyperpigmentation | 1 | 2024 | 27 | 0.210 |
Why?
| | Piperidines | 2 | 2018 | 219 | 0.200 |
Why?
| | Lymph Nodes | 1 | 2006 | 501 | 0.200 |
Why?
| | Dacarbazine | 7 | 2012 | 100 | 0.200 |
Why?
| | Genomics | 4 | 2024 | 831 | 0.200 |
Why?
| | Mice, Nude | 4 | 2020 | 677 | 0.200 |
Why?
| | Hair Follicle | 3 | 2020 | 48 | 0.200 |
Why?
| | Exons | 3 | 2019 | 362 | 0.200 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1465 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2026 | 915 | 0.200 |
Why?
| | Melatonin | 3 | 1994 | 163 | 0.200 |
Why?
| | Stem Cells | 4 | 2017 | 621 | 0.200 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 220 | 0.190 |
Why?
| | Burns | 7 | 1997 | 371 | 0.190 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 21 | 0.190 |
Why?
| | Flavonoids | 1 | 2003 | 86 | 0.190 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 164 | 0.190 |
Why?
| | Pedigree | 3 | 2024 | 515 | 0.180 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 437 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 256 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 881 | 0.180 |
Why?
| | Retrospective Studies | 17 | 2025 | 17149 | 0.180 |
Why?
| | Lordosis | 1 | 2022 | 16 | 0.180 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 419 | 0.180 |
Why?
| | Spondylolisthesis | 1 | 2021 | 8 | 0.180 |
Why?
| | Cervical Vertebrae | 2 | 2021 | 161 | 0.180 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 7 | 0.180 |
Why?
| | Clone Cells | 7 | 2010 | 263 | 0.180 |
Why?
| | Spinal Cord Diseases | 1 | 2021 | 41 | 0.170 |
Why?
| | Animals | 35 | 2026 | 37948 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 1145 | 0.170 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 628 | 0.170 |
Why?
| | Registries | 3 | 2020 | 2392 | 0.170 |
Why?
| | Liver Neoplasms | 3 | 2026 | 777 | 0.160 |
Why?
| | Signal Transduction | 8 | 2026 | 5185 | 0.160 |
Why?
| | Risk Factors | 8 | 2020 | 10796 | 0.160 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1766 | 0.160 |
Why?
| | Interleukin-1 | 2 | 2019 | 961 | 0.160 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1044 | 0.160 |
Why?
| | Sonication | 1 | 2020 | 12 | 0.160 |
Why?
| | Leukemia | 8 | 1988 | 245 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2020 | 40 | 0.160 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 29 | 0.160 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 82 | 0.150 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1468 | 0.150 |
Why?
| | Turner Syndrome | 1 | 2001 | 64 | 0.150 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 881 | 0.150 |
Why?
| | Arthroplasty, Replacement, Finger | 1 | 2019 | 3 | 0.150 |
Why?
| | Finger Joint | 1 | 2019 | 9 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 70 | 0.150 |
Why?
| | Aniline Compounds | 1 | 2020 | 121 | 0.150 |
Why?
| | Finger Phalanges | 1 | 2019 | 13 | 0.150 |
Why?
| | beta Catenin | 2 | 2020 | 252 | 0.150 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 442 | 0.150 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 98 | 0.150 |
Why?
| | Heart Neoplasms | 2 | 1999 | 56 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 59 | 0.150 |
Why?
| | Bone Density | 2 | 2020 | 484 | 0.140 |
Why?
| | RNA | 2 | 2016 | 926 | 0.140 |
Why?
| | Visual Analog Scale | 1 | 2019 | 34 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2020 | 141 | 0.140 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 38 | 0.140 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 27 | 0.140 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2019 | 33 | 0.140 |
Why?
| | Ipilimumab | 1 | 2018 | 40 | 0.140 |
Why?
| | Reoperation | 2 | 2019 | 624 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 66 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2022 | 3603 | 0.130 |
Why?
| | Hospital Costs | 1 | 2018 | 125 | 0.130 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 48 | 0.130 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Immune Tolerance | 3 | 2026 | 381 | 0.130 |
Why?
| | Receptors, Androgen | 1 | 1998 | 148 | 0.130 |
Why?
| | Colony-Forming Units Assay | 19 | 1988 | 95 | 0.130 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 76 | 0.130 |
Why?
| | Bone Marrow Cells | 17 | 1983 | 321 | 0.130 |
Why?
| | Adolescent | 35 | 2025 | 22409 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 195 | 0.130 |
Why?
| | Biofilms | 1 | 2020 | 301 | 0.130 |
Why?
| | Burns, Electric | 3 | 1986 | 25 | 0.130 |
Why?
| | Low Back Pain | 1 | 2019 | 106 | 0.130 |
Why?
| | Bone Marrow | 14 | 1983 | 306 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 247 | 0.120 |
Why?
| | Cisplatin | 4 | 2006 | 339 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2018 | 255 | 0.120 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 23 | 0.120 |
Why?
| | Apoptosis | 4 | 2018 | 2397 | 0.120 |
Why?
| | Membrane Proteins | 4 | 2020 | 1159 | 0.120 |
Why?
| | Freezing | 4 | 2014 | 86 | 0.120 |
Why?
| | Benzamides | 2 | 2008 | 224 | 0.120 |
Why?
| | Preservation, Biological | 3 | 2014 | 7 | 0.120 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 293 | 0.120 |
Why?
| | Pain Measurement | 1 | 2019 | 554 | 0.120 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 272 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 262 | 0.120 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 85 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2000 | 733 | 0.120 |
Why?
| | Adenine | 1 | 2018 | 337 | 0.120 |
Why?
| | Drug Synergism | 4 | 2018 | 352 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 127 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2017 | 396 | 0.120 |
Why?
| | Interferon Type I | 4 | 1994 | 146 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.110 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 99 | 0.110 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2660 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 973 | 0.110 |
Why?
| | Cell Cycle | 3 | 2010 | 595 | 0.110 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1327 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1322 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 848 | 0.110 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 80 | 0.110 |
Why?
| | Leukocyte Count | 20 | 1988 | 315 | 0.110 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 20 | 0.110 |
Why?
| | Fenretinide | 1 | 2014 | 3 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 266 | 0.110 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 562 | 0.110 |
Why?
| | Cell Division | 11 | 1998 | 753 | 0.110 |
Why?
| | Desiccation | 1 | 2014 | 25 | 0.110 |
Why?
| | Receptors, Lysophosphatidic Acid | 2 | 2026 | 40 | 0.110 |
Why?
| | Survival Analysis | 6 | 2010 | 1370 | 0.110 |
Why?
| | Cell Survival | 8 | 2018 | 1092 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 691 | 0.110 |
Why?
| | Lymphoma | 4 | 1991 | 233 | 0.110 |
Why?
| | Peptides | 2 | 2008 | 989 | 0.100 |
Why?
| | Survival Rate | 8 | 2024 | 2089 | 0.100 |
Why?
| | Cohort Studies | 3 | 2024 | 5957 | 0.100 |
Why?
| | Child | 17 | 2025 | 22600 | 0.100 |
Why?
| | Perineum | 1 | 1993 | 37 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 400 | 0.100 |
Why?
| | Basigin | 1 | 2013 | 24 | 0.100 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2019 | 0.100 |
Why?
| | Mohs Surgery | 1 | 2013 | 29 | 0.100 |
Why?
| | Internet | 1 | 2018 | 698 | 0.100 |
Why?
| | Extracellular Space | 1 | 2013 | 119 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2489 | 0.090 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 53 | 0.090 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 130 | 0.090 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 8 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 323 | 0.090 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 59 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2023 | 990 | 0.090 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.090 |
Why?
| | BRCA1 Protein | 1 | 2013 | 82 | 0.090 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.090 |
Why?
| | Vitamins | 1 | 1994 | 176 | 0.090 |
Why?
| | Alleles | 2 | 2022 | 886 | 0.090 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 20 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 176 | 0.090 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.090 |
Why?
| | Decision Making | 1 | 2019 | 973 | 0.090 |
Why?
| | Pyrimidinones | 2 | 2025 | 125 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 643 | 0.090 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 126 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 828 | 0.090 |
Why?
| | Peer Review | 1 | 2012 | 45 | 0.090 |
Why?
| | Phenotype | 5 | 2024 | 3147 | 0.090 |
Why?
| | Immunotoxins | 1 | 1991 | 55 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2922 | 0.090 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 409 | 0.090 |
Why?
| | Malpractice | 1 | 2012 | 44 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 32 | 0.090 |
Why?
| | History, 21st Century | 1 | 2012 | 220 | 0.080 |
Why?
| | Keratinocytes | 2 | 2024 | 250 | 0.080 |
Why?
| | Agranulocytosis | 6 | 1986 | 30 | 0.080 |
Why?
| | United States | 3 | 2020 | 16018 | 0.080 |
Why?
| | History, 20th Century | 1 | 2012 | 327 | 0.080 |
Why?
| | Cyclosporine | 1 | 1991 | 255 | 0.080 |
Why?
| | Pancreatitis | 1 | 1991 | 145 | 0.080 |
Why?
| | Blast Crisis | 1 | 1990 | 34 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 2117 | 0.080 |
Why?
| | Time Factors | 15 | 2019 | 7140 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 2 | 1983 | 260 | 0.080 |
Why?
| | Bacterial Infections | 4 | 1989 | 247 | 0.080 |
Why?
| | Glycoproteins | 5 | 1977 | 353 | 0.080 |
Why?
| | Vitamin E | 2 | 1994 | 123 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3729 | 0.080 |
Why?
| | Neoplasms | 5 | 2018 | 2873 | 0.080 |
Why?
| | Cells, Cultured | 12 | 2019 | 4110 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 768 | 0.070 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 12 | 0.070 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1363 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 770 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2754 | 0.070 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 475 | 0.070 |
Why?
| | Osteonecrosis | 2 | 1986 | 23 | 0.070 |
Why?
| | Cell Differentiation | 7 | 2015 | 2037 | 0.070 |
Why?
| | Neutrophils | 8 | 1988 | 1118 | 0.070 |
Why?
| | Lithium | 5 | 1986 | 40 | 0.070 |
Why?
| | Cyclin D | 1 | 2008 | 8 | 0.070 |
Why?
| | Lymphocytes | 7 | 2006 | 379 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2013 | 632 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2177 | 0.070 |
Why?
| | Surgical Flaps | 3 | 1986 | 142 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1726 | 0.070 |
Why?
| | Risk | 2 | 2019 | 911 | 0.070 |
Why?
| | S Phase | 1 | 2008 | 80 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 848 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 353 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2870 | 0.070 |
Why?
| | Skull | 2 | 1986 | 161 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 26 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 191 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 15 | 0.070 |
Why?
| | Australia | 2 | 2023 | 287 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 15 | 0.060 |
Why?
| | Computational Biology | 3 | 2019 | 681 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 150 | 0.060 |
Why?
| | Oligosaccharides | 1 | 2007 | 60 | 0.060 |
Why?
| | Cell Movement | 5 | 2015 | 959 | 0.060 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.060 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 13 | 0.060 |
Why?
| | Factor VIII | 1 | 1987 | 105 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 245 | 0.060 |
Why?
| | Cell Self Renewal | 2 | 2017 | 52 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2008 | 507 | 0.060 |
Why?
| | Vaccinia virus | 2 | 1998 | 35 | 0.060 |
Why?
| | Health Education | 1 | 1990 | 345 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 532 | 0.060 |
Why?
| | Disease Progression | 2 | 2013 | 2847 | 0.060 |
Why?
| | Education, Medical | 1 | 1990 | 273 | 0.060 |
Why?
| | Quinazolines | 1 | 2008 | 266 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 147 | 0.060 |
Why?
| | Binding Sites | 2 | 2008 | 1307 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2006 | 123 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 14122 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 44 | 0.060 |
Why?
| | Models, Biological | 4 | 2019 | 1811 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 464 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 25 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 22 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 22 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 420 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 164 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 107 | 0.060 |
Why?
| | Fasciotomy | 1 | 1985 | 24 | 0.060 |
Why?
| | Water Microbiology | 1 | 2006 | 93 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 572 | 0.060 |
Why?
| | Hemophilia A | 1 | 1987 | 147 | 0.060 |
Why?
| | Forearm Injuries | 1 | 1985 | 6 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 68 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1484 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3888 | 0.060 |
Why?
| | Chromates | 1 | 1985 | 2 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1046 | 0.060 |
Why?
| | Pruritus | 1 | 2025 | 59 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 28 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 111 | 0.060 |
Why?
| | Chromium | 1 | 1985 | 16 | 0.050 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 503 | 0.050 |
Why?
| | Kidney Transplantation | 1 | 1991 | 709 | 0.050 |
Why?
| | Karyotyping | 4 | 1994 | 105 | 0.050 |
Why?
| | Forearm | 1 | 1985 | 140 | 0.050 |
Why?
| | Infant | 2 | 2019 | 10023 | 0.050 |
Why?
| | Axilla | 1 | 2004 | 51 | 0.050 |
Why?
| | Hand Injuries | 1 | 1985 | 33 | 0.050 |
Why?
| | Wrist | 1 | 1985 | 60 | 0.050 |
Why?
| | Burns, Chemical | 1 | 1985 | 32 | 0.050 |
Why?
| | Macrophages | 4 | 1988 | 1496 | 0.050 |
Why?
| | Protein Transport | 2 | 2018 | 437 | 0.050 |
Why?
| | Skin Transplantation | 1 | 1985 | 85 | 0.050 |
Why?
| | Acute Disease | 6 | 1991 | 1029 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 197 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 117 | 0.050 |
Why?
| | Monocytes | 5 | 1983 | 536 | 0.050 |
Why?
| | Blood Cell Count | 5 | 1995 | 55 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2137 | 0.050 |
Why?
| | Phosphorylation | 2 | 2018 | 1704 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 15 | 0.050 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 691 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 339 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 106 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 63 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 480 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 402 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 201 | 0.050 |
Why?
| | Urine | 4 | 1973 | 64 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2909 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 24 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 90 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 28 | 0.050 |
Why?
| | Escherichia coli | 3 | 2006 | 854 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 69 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 108 | 0.050 |
Why?
| | Mice, Inbred C57BL | 5 | 2026 | 5967 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1467 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 485 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 155 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 272 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 971 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 105 | 0.050 |
Why?
| | Receptors, Melanocortin | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Corticotropin | 1 | 2002 | 2 | 0.050 |
Why?
| | Vitamin A | 1 | 1982 | 59 | 0.050 |
Why?
| | Genes, cdc | 1 | 2002 | 11 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 376 | 0.050 |
Why?
| | Diskectomy | 1 | 2021 | 24 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2002 | 53 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 210 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 50 | 0.040 |
Why?
| | Leukocytosis | 4 | 1974 | 32 | 0.040 |
Why?
| | Neck Pain | 1 | 2021 | 30 | 0.040 |
Why?
| | Gene Expression | 3 | 2008 | 1476 | 0.040 |
Why?
| | Antigens | 2 | 1983 | 347 | 0.040 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 1056 | 0.040 |
Why?
| | Isotretinoin | 2 | 1994 | 26 | 0.040 |
Why?
| | Incidence | 3 | 2009 | 2892 | 0.040 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 17 | 0.040 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 43 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4539 | 0.040 |
Why?
| | Bone Neoplasms | 1 | 1983 | 255 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2002 | 122 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 351 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 23 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 550 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 14 | 0.040 |
Why?
| | Administration, Oral | 5 | 1995 | 851 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Eosinophils | 1 | 1983 | 316 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 8 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 5 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 55 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 13 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 119 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 95 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 56 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 685 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 148 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 3 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 31 | 0.040 |
Why?
| | Age Factors | 4 | 2019 | 3329 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 218 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 33 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 820 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 21 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 3183 | 0.040 |
Why?
| | Joint Prosthesis | 1 | 2019 | 22 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 184 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2815 | 0.040 |
Why?
| | Carotenoids | 2 | 1994 | 48 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 140 | 0.040 |
Why?
| | Finger Injuries | 1 | 2019 | 26 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 265 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 90 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2026 | 3109 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 168 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1186 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 45 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 36 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 100 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2019 | 125 | 0.030 |
Why?
| | Arthritis | 1 | 2019 | 96 | 0.030 |
Why?
| | Heterografts | 1 | 2018 | 143 | 0.030 |
Why?
| | Chromosome Deletion | 2 | 1994 | 124 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 132 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 496 | 0.030 |
Why?
| | Levamisole | 1 | 1977 | 21 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 369 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 185 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 91 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 36 | 0.030 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 81 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 167 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 386 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 79 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 1998 | 166 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 117 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 151 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 67 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 423 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 172 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 18 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 38 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 52 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 66 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 202 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 132 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 319 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 76 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 15 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 69 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 978 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 160 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 75 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1268 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 438 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 171 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 779 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 392 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 21 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 192 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 184 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 65 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 258 | 0.030 |
Why?
| | Veins | 1 | 1995 | 69 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 8 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 8 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 273 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 2243 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 422 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 33 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 66 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 366 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 103 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 3 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 547 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 15 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 20 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 341 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 28 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 43 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 19 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 13 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 127 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 42 | 0.020 |
Why?
| | Estrogens | 1 | 2016 | 364 | 0.020 |
Why?
| | Anus Neoplasms | 1 | 1993 | 32 | 0.020 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 124 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 1994 | 318 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 1994 | 118 | 0.020 |
Why?
| | Administration, Intranasal | 3 | 1989 | 93 | 0.020 |
Why?
| | Gonanes | 1 | 2013 | 23 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 190 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2013 | 81 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 35 | 0.020 |
Why?
| | Specimen Handling | 1 | 2014 | 187 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1886 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 63 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 29 | 0.020 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 42 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 111 | 0.020 |
Why?
| | Mechlorethamine | 3 | 1982 | 52 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2012 | 29 | 0.020 |
Why?
| | Phenytoin | 2 | 1962 | 21 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1998 | 1106 | 0.020 |
Why?
| | Individuality | 1 | 1994 | 149 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 1994 | 171 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 85 | 0.020 |
Why?
| | Flow Cytometry | 3 | 2008 | 1154 | 0.020 |
Why?
| | Vaccines | 1 | 1997 | 388 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 50 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 246 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 158 | 0.020 |
Why?
| | Iron | 3 | 1989 | 358 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 91 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 729 | 0.020 |
Why?
| | Patient Discharge | 1 | 2018 | 985 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 297 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 43 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 454 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 368 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 202 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 200 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 221 | 0.020 |
Why?
| | Sodium | 2 | 1962 | 198 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 269 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 23 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 43 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 256 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 380 | 0.020 |
Why?
| | Bacteria | 1 | 1977 | 894 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 128 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 610 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1161 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 16 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 34 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 52 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 256 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 153 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 507 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 631 | 0.020 |
Why?
| | California | 1 | 1991 | 471 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 430 | 0.020 |
Why?
| | Hepatectomy | 2 | 1962 | 274 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 34 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 27 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 246 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1501 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 510 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 13 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 751 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 191 | 0.020 |
Why?
| | Bone Regeneration | 2 | 1986 | 28 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 115 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 88 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4558 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 189 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 141 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 680 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 223 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 524 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 12 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 113 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 164 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 142 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 272 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 25 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 112 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 151 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 33 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 312 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.020 |
Why?
| | Enterobacter aerogenes | 1 | 2006 | 3 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 112 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 49 | 0.010 |
Why?
| | Electric Injuries | 1 | 1986 | 2 | 0.010 |
Why?
| | Hydroxyurea | 2 | 1984 | 34 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 835 | 0.010 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.010 |
Why?
| | MART-1 Antigen | 1 | 2005 | 8 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 71 | 0.010 |
Why?
| | Hemoglobins | 1 | 1988 | 381 | 0.010 |
Why?
| | Metaproterenol | 1 | 1985 | 1 | 0.010 |
Why?
| | Culture Media | 4 | 1977 | 163 | 0.010 |
Why?
| | Reference Standards | 1 | 2006 | 178 | 0.010 |
Why?
| | Extremities | 1 | 2006 | 140 | 0.010 |
Why?
| | Double-Blind Method | 3 | 1998 | 2033 | 0.010 |
Why?
| | Prospective Studies | 4 | 2005 | 7994 | 0.010 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 441 | 0.010 |
Why?
| | Wrist Injuries | 1 | 1985 | 23 | 0.010 |
Why?
| | Lower Extremity | 1 | 2009 | 440 | 0.010 |
Why?
| | Platelet Count | 2 | 1986 | 94 | 0.010 |
Why?
| | Edetic Acid | 1 | 1985 | 46 | 0.010 |
Why?
| | Fatigue | 1 | 2007 | 363 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 552 | 0.010 |
Why?
| | Accidents, Occupational | 1 | 1985 | 17 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 967 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1988 | 423 | 0.010 |
Why?
| | Blood Platelets | 3 | 1974 | 379 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 249 | 0.010 |
Why?
| | Erythrocytes | 3 | 1981 | 750 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 498 | 0.010 |
Why?
| | Spleen | 2 | 1981 | 510 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 154 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 379 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 38 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 519 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 309 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 152 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 175 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 8 | 0.010 |
Why?
| | Necrosis | 1 | 1985 | 243 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 427 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 114 | 0.010 |
Why?
| | Blood Vessels | 1 | 1985 | 167 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 8 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 776 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 168 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 36 | 0.010 |
Why?
| | Liver | 2 | 1962 | 1889 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 19 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 9 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 406 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 62 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 15 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 47 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 592 | 0.010 |
Why?
| | Absorption | 1 | 1982 | 61 | 0.010 |
Why?
| | Sodium, Dietary | 1 | 1962 | 37 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 57 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 776 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 253 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 257 | 0.010 |
Why?
| | Ischemia | 1 | 1985 | 422 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 172 | 0.010 |
Why?
| | Pain | 1 | 2007 | 785 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 479 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 50 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 296 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1033 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3414 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 9 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1079 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 223 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 16 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 146 | 0.010 |
Why?
| | Regeneration | 1 | 1962 | 195 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 61 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 152 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 62 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 391 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 2 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 82 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 7122 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 3 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 405 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 24 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 49 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 176 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 75 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 643 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1505 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 364 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 39 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 375 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 70 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 108 | 0.010 |
Why?
| | Bacterial Physiological Phenomena | 1 | 1978 | 62 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 2 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 38 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 170 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 924 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 573 | 0.010 |
Why?
| | Staphylococcus | 1 | 1977 | 75 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 397 | 0.010 |
Why?
| | Agar | 1 | 1977 | 11 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 562 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 667 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 629 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1170 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 59 | 0.010 |
Why?
| | Groin | 1 | 1995 | 13 | 0.010 |
Why?
| | Phagocytosis | 1 | 1977 | 296 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 1977 | 176 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 15 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 6 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 5 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 587 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 2 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 7 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 18 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 11 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 176 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 28 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 61 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 129 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 24 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 55 | 0.010 |
Why?
| | Child, Preschool | 3 | 1985 | 11790 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 98 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 1774 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 117 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 218 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1984 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 297 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 9 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 115 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 124 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 306 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 393 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 398 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2591 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1339 | 0.000 |
Why?
| | Arm | 2 | 1985 | 110 | 0.000 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 2 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1989 | 87 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 193 | 0.000 |
Why?
| | Debridement | 1 | 1989 | 85 | 0.000 |
Why?
| | Ferritins | 1 | 1989 | 70 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 291 | 0.000 |
Why?
| | Perfusion | 1 | 1970 | 249 | 0.000 |
Why?
| | Skin | 1 | 1994 | 762 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 4 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 960 | 0.000 |
Why?
| | Scalp | 1 | 1986 | 38 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 25 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 33 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 36 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 12 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 69 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 48 | 0.000 |
Why?
| | Angiography | 1 | 1985 | 208 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 70 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 3 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 11 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 188 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 25 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 2 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 61 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 56 | 0.000 |
Why?
| | Rats | 2 | 1962 | 5570 | 0.000 |
Why?
| | Arteries | 1 | 1985 | 258 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2821 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1985 | 513 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 177 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 15 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2950 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 313 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 13 | 0.000 |
Why?
| | Fever | 1 | 1984 | 313 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 221 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 853 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 396 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 57 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 303 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 365 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 11 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 38 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1766 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 314 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 664 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 208 | 0.000 |
Why?
| | Blood | 1 | 1977 | 106 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 21 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 94 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 320 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1447 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 597 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 19 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 11 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 1136 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 58 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 66 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1810 | 0.000 |
Why?
| | Leg | 1 | 1972 | 240 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 60 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 139 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 374 | 0.000 |
Why?
| | Swine | 1 | 1970 | 828 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 880 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|